Haines, Rachel H., Thomas, Kim S., Montgomery, Alan A., Ravenscroft, Jane C., Akram, Perways, Chalmers, J.R., Whitman, Diane, Duley, Lelia, Eleftheriadou, Viktoria, Meakin, Garry, Mitchell, Eleanor, White, Jennifer, Rogers, Andy, Sach, Tracey, Santer, Miriam, Tan, Wei, Hepburn, Trish, Williams, Hywel C. and Batchelor, Jonathan M.
(2018)
Home interventions and light therapy for treatment of vitiligo (HI-Light Vitiligo Trial): study protocol for a randomized controlled trial.
BMJ Open, 8
(4).
e018649/1-e018649/13.
ISSN 2044-6055
Abstract
Vitiligo is a condition resulting in white patches on the skin. People with vitiligo can suffer from low self-esteem, psychological disturbance and diminished quality of life. Vitiligo is often poorly managed, partly due to lack of high quality evidence to inform clinical care. We describe here a large, independent, randomised controlled trial (RCT) assessing the comparative effectiveness of potent topical corticosteroid, home-based hand-held narrowband ultraviolet B-light (NB-UVB) or combination of the two, for the management of vitiligo.
Methods and Analysis
The HI-Light Vitiligo Trial is a multi-centre, three-arm, parallel group, pragmatic, placebo-controlled RCT. 516 adults and children with actively spreading, but limited, vitiligo are randomised (1:1:1) to one of three groups: mometasone furoate 0.1% ointment plus dummy NB-UVB light, vehicle ointment plus NB-UVB light, or mometasone furoate 0.1% ointment plus NB-UVB light. Treatment of up to three patches of vitiligo is continued for up to 9 months with clinic visits at baseline, 3, 6 and 9 months and four post treatment questionnaires.
The HI-Light Vitiligo Trial assesses outcomes included in the vitiligo core outcome set and places emphasis on participants’ views of treatment success. The primary outcome is proportion of participants achieving treatment success (patient-rated Vitiligo Noticeability Scale) for a target patch of vitiligo at 9 months with further independent blinded assessment using digital images of the target lesion before and after treatment. Secondary outcomes include time to onset of treatment response, treatment success by body region, percentage repigmentation, quality of life, time-burden of treatment, maintenance of response, safety, and within-trial cost effectiveness.
Ethics and Dissemination
Approvals were granted by East Midlands–Derby Research Ethics Committee (14/EM/1173) and the MHRA (EudraCT 2014-003473-42). The trial was registered 8th January 2015 ISRCTN (17160087). Results will be published in full as open access in the NIHR Journal library and elsewhere.
| Item Type: |
Article
|
| Keywords: |
Randomised controlled trial; Vitiligo; Topical corticosteroid; NB-UVB, combination therapy; Pragmatic |
| Schools/Departments: |
University of Nottingham, UK > Faculty of Medicine and Health Sciences > School of Medicine > Division of Rheumatology, Orthopaedics and Dermatology
University of Nottingham, UK > Faculty of Medicine and Health Sciences > School of Medicine > Units > Clinical Trials Unit |
| Identification Number: |
https://doi.org/10.1136/bmjopen-2017-018649 |
| Depositing User: |
Eprints, Support
|
| Date Deposited: |
09 Nov 2017 14:40 |
| Last Modified: |
28 Apr 2018 12:10 |
| URI: |
https://eprints.nottingham.ac.uk/id/eprint/48028 |
Actions (Archive Staff Only)
 |
Edit View |
Tools
Tools
